Blog / Nanomedicines

Nanomedicines

Insights and perspectives from our team on industry trends and scientific advances.

The Evolution of Precision: Why Targeted Nanomedicine is the 2026 Standard

The Evolution of Precision: Why Targeted Nanomedicine is the 2026 Standard

In the evolving oncology landscape, the primary challenge remains the systemic toxicity and narrow therapeutic index of traditional chemotherapeutics. As molecules in the oncology pipeline become increasingly complex and often highly potent, the industry is shifting toward targeted nanomedicine to improve biodistribution. Nanomedicines offer a sophisticated solution by encapsulating these “hard-to-make” drugs within protective carriers, […]

Read more May 18, 2026
From Bench to Bulk: Overcoming the Scale-Up Barriers of Lipid Nanoparticles (LNPs)

From Bench to Bulk: Overcoming the Scale-Up Barriers of Lipid Nanoparticles (LNPs)

In the modern oncology and rare disease landscape, the most promising therapeutic candidates—such as mRNA, siRNA, and high-potency APIs (HPAPIs)—often suffer from poor aqueous solubility or rapid systemic degradation. Lipid Nanoparticles (LNPs) have emerged as the gold standard for delivering these “hard-to-make” drugs, yet many programs stall during the transition from laboratory bench to clinical production. The […]

Read more May 15, 2026